Breaking Down Barriers - A Casual Conversation with LoQus23

Breaking Down Barriers exists to bring you conversations about different educational and social barriers and stigmas of Huntingon's disease. We sat down with David Reynolds to introduce LoQus23 Therapeutics to the HD community.
⁠
Established in 2019, LoQus23 Therapeutics has established a platform of assays and a small molecule series of MutSα and MutSβ inhibitors which are therapeutically relevant in up to 30 triplet repeat diseases, including Huntington’s Disease. By targeting somatic expansion, LoQus23 is hoping to slow or even halt the onset and progression of Huntington’s disease, a concept supported by genetic studies and recently strengthened by pre-clinical models.⁠
⁠
Read the complete press release including multiple languages through HDYO translation software at HDYO.ORG.
David mentions the video from the HDSA Convention. To view, click here: vimeo.com/4284...
Breaking Down Barriers is sponsored by Roche, Sage Therapeutics, Teva Pharmaceuticals, uniQure, Wave Life Sciences, Neurocrine Biosciences, Griffin Foundation and PTC Therapeutics.